Artemisia annua, an inexpensive alternative to Covid-19 - very promising leads!
(Pre-publication 8 January 2021)
UPDATE ON CLINICAL TRIALS
University of Kentucky, USA & Max Planck Institute, Germany
Columbia University, University of Washington & Worcester Polytechnic Institute, USA
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico
Mateon Therapeutics, California, USA
The laboratory has shown potent in vitro activity to inhibit the coronavirus that causes Covid-19. It has initiated an in vivo study to establish the efficacy of artemisinin as an affordable first-line treatment in India.
- Mateon expands its Covid-19 therapeutic program to include artemisinin, April 8th, 2020
- Mateon Therapeutics to fund observational studies of Artemisinin in developing countries, July 13th, 2020
- Patient Enrollment in India, Sept 14th, 2020
University Of California-Santa Clara, USA
“The team has selected a list of priority botanicals for deep analysis, focusing on several well-known natural products that have been used for anti-inflammatory effects or for enhancing the immune system. The list includes sweet Annie (Artemisia annua, also called sweet wormwood)”.
Press Release University Of California, 8 July 2020
Europe / South Africa
Institut Max Planck & Freie Universität Berlin (Germany) & University of Copenhagen (Denmark)
https://www.biorxiv.org/content/10.1101/2020.10.05.326637v1 (pre-publication, 5 October 2020)
North West University, South Africa
“We are raising funds to scientifically investigate the potential to develop Artemisia into an effective treatment of COVID-19. All funds will be managed by North West University”, Prof Frank van der Kooy.
Presentation of research progress
- accelerate research into Artemisia herbal tea
- oversee and increase its sustainable production in malaria endemic countries through Houses of Artemisia, local centres of expertise, which coordinate knowledge and distribution of the plant.